Drilldown: Medicines
Use the filters below to narrow your results.
generic:
7-Hydroxymitragynine (1) ·
Acacia confusa (1) ·
Allopurinol (1) ·
Amanita muscaria (1) ·
Ayahuasca (1) ·
Blue lotus (1) ·
Calea zacatechichi (1) ·
Colchicine (1) ·
Datura (1) ·
Harmaline (1) ·
Harmine (1) ·
Hawaiian Baby Woodrose (1) ·
Iboga (1) ·
Kava (1) ·
Kratom (1) ·
Mitragynine (1) ·
Morning Glory (1) ·
Myristicin (1) ·
Peyote (1) ·
Psilocybin mushrooms (1) ·
Salvia divinorum (1) ·
San Pedro cactus (1) ·
Syrian rue (1) ·
Tetrahydroharmine (1) ·
Yopo (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Apomorphine and nuciferine; dopaminergic activity (1) ·
Contains atropine, scopolamine, hyoscyamine (1) ·
Contains bufotenin and DMT (1) ·
Contains harmine, harmaline, tetrahydroharmine (1) ·
Contains ibogaine; kappa-opioid agonist (1) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Contains muscimol and ibotenic acid (1) ·
Contains psilocybin and psilocin (1) ·
Contains salvinorin A (1) ·
DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) ·
DMT-containing plant used in psychedelic preparations (1) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Mechanism incompletely understood (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Partial MAOI; anticholinergic effects (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Potent mu-opioid receptor agonist (1) ·
Reversible MAO-A inhibitor; beta-carboline (1) ·
Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) ·
Weak serotonin reuptake inhibitor; beta-carboline (1)
uses:
None (23) ·
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1) ·
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)
starting dose:
None (23) ·
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) ·
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (23) ·
Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 25 results in range #1 to #25.